anastrozole has been researched along with Neoplasms in 7 studies
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The PARP inhibitor olaparib is efficacious as monotherapy and has potential application in combination with endocrine therapy for the treatment of breast cancer." | 5.27 | Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. ( Bailey, C; Birkett, J; De Grève, J; De Vos, FYFL; Dean, E; Dirix, L; Goessl, C; Grundtvig-Sørensen, P; Italiano, A; Jerusalem, G; Learoyd, M; Leunen, K; Molife, LR; Plummer, R; Rolfo, C; Rottey, S; Spencer, S; Spicer, J; Verheul, HM, 2018) |
| "Aromatase (estrogen synthetase) inhibitors are superior to tamoxifen in terms of both efficacy and toxicity in the treatment of advanced breast cancer and also in the neoadjuvant setting." | 3.72 | Prevention strategies with aromatase inhibitors. ( Goss, PE; Strasser-Weippl, K, 2004) |
| "Drugs used to treat cancer may affect the skeleton in several ways, the most important being a decrease in sex steroid levels." | 2.44 | Skeletal effects of drugs to treat cancer. ( Vestergaard, P, 2008) |
| "The condition is characterized by uterine leiomyomas associated with the development, typically years later, of slow-growing metastatic lesions." | 2.42 | Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. ( Christopoulos, S; Rivera, JA; Small, D; Trifiro, M, 2004) |
| "In Model 1, MCF-7 or T47D cancer cells were treated with Anastrozole, then exposed to whole blood and platelet-rich plasma, modelling platelet engagement in the tumour bed." | 1.72 | Modelling the procoagulatory effect of Anastrozole relative to ERα and ERβ expression in breast cancer cells. ( Augustine, TN; Pather, K, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Almutlaq, RN | 1 |
| Newell-Fugate, AE | 1 |
| Evans, LC | 1 |
| Fatima, H | 1 |
| Gohar, EY | 1 |
| Pather, K | 1 |
| Augustine, TN | 1 |
| Plummer, R | 1 |
| Verheul, HM | 1 |
| De Vos, FYFL | 1 |
| Leunen, K | 1 |
| Molife, LR | 1 |
| Rolfo, C | 1 |
| Grundtvig-Sørensen, P | 1 |
| De Grève, J | 1 |
| Rottey, S | 1 |
| Jerusalem, G | 1 |
| Italiano, A | 1 |
| Spicer, J | 1 |
| Dirix, L | 1 |
| Goessl, C | 1 |
| Birkett, J | 1 |
| Spencer, S | 1 |
| Learoyd, M | 1 |
| Bailey, C | 1 |
| Dean, E | 1 |
| Vestergaard, P | 1 |
| Gheita, TA | 1 |
| Ezzat, Y | 1 |
| Sayed, S | 1 |
| El-Mardenly, G | 1 |
| Hammam, W | 1 |
| Goss, PE | 1 |
| Strasser-Weippl, K | 1 |
| Rivera, JA | 1 |
| Christopoulos, S | 1 |
| Small, D | 1 |
| Trifiro, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Non-randomised, Parallel Group, Multicentre, Phase I Study to Assess the Safety and Effect of Olaparib at Steady State on the Pharmacokinetics of the Anti-hormonal Agents Anastrozole, Letrozole and Tamoxifen at Steady State, and the Effect [NCT02093351] | Phase 1 | 79 participants (Actual) | Interventional | 2014-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Olaparib AUC0-τ, in the presence and absence of co-administered anastrozole, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 2 - Olaparib (Treatment Period 1) | 55.49 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 44.33 |
Olaparib Cmax ss in the presence and absence of co-administered anastrozole, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 2 - Olaparib (Treatment Period 1) | 9.490 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 8.256 |
Olaparib AUC0-τ, in the presence and absence of co-administered letrozole, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Olaparib (Treatment Period 1) | 61.77 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 67.82 |
Olaparib Cmax ss in the presence and absence of co-administered letrozole, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Olaparib (Treatment Period 1) | 10.05 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 10.48 |
Anastrozole Area under plasma concentration-time curve over the dosing interval at steady state (AUC0-τ), in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 2 - Anastrozole Alone (Treatment Period 2) | 696.8 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 582.5 |
Anastrozole maximum plasma concentration at steady state (Cmax ss) in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24
| Intervention | micrograms per millilitre (mcg/mL) (Geometric Mean) |
|---|---|
| Cohort 2 - Anastrozole Alone (Treatment Period 2) | 40.98 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 35.83 |
Letrozole AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Letrozole Alone (Treatment Period 2) | 2292 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 2167 |
Letrozole Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Letrozole Alone (Treatment Period 2) | 118.9 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 111.8 |
Olaparib AUC0-τ, in the presence and absence of co-administered tamoxifen, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 1 - Olaparib (Treatment Period 1) | 62.12 |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 42.27 |
Olaparib Cmax ss in the presence and absence of co-administered tamoxifen, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 1 - Olaparib (Treatment Period 1) | 9.456 |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 7.216 |
Tamoxifen, N-DMT and endoxifen AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31
| Intervention | microgram x hour/millilitre (mcg*h/mL) (Geometric Mean) | ||
|---|---|---|---|
| PK analysis of tamoxifen | PK analysis of N-DMT | PK analysis of endoxifen | |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 2751 | 2955 | 115.8 |
| Cohort 1 - Tamoxifen Alone (Treatment Period 2) | 2233 | 3189 | 119.3 |
Tamoxifen, N-desmethyl tamoxifen (N-DMT) and endoxifen Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31
| Intervention | mcg/mL (Geometric Mean) | ||
|---|---|---|---|
| PK analysis of tamoxifen | PK analysis of N-DMT | PK analysis of endoxifen | |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 154.2 | 149.1 | 5.727 |
| Cohort 1 - Tamoxifen Alone (Treatment Period 2) | 130.3 | 162.9 | 5.923 |
2 reviews available for anastrozole and Neoplasms
| Article | Year |
|---|---|
Skeletal effects of drugs to treat cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Diseases, Meta | 2008 |
Skeletal effects of drugs to treat cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Diseases, Meta | 2008 |
Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brachial Plexus Neuropath | 2004 |
Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brachial Plexus Neuropath | 2004 |
1 trial available for anastrozole and Neoplasms
| Article | Year |
|---|---|
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relations | 2018 |
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relations | 2018 |
4 other studies available for anastrozole and Neoplasms
| Article | Year |
|---|---|
Aromatase inhibition increases blood pressure and markers of renal injury in female rats.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Biomarkers; Blood Pressure; Estrogens; Female; Hypertens | 2022 |
Aromatase inhibition increases blood pressure and markers of renal injury in female rats.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Biomarkers; Blood Pressure; Estrogens; Female; Hypertens | 2022 |
Modelling the procoagulatory effect of Anastrozole relative to ERα and ERβ expression in breast cancer cells.
Topics: Anastrozole; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Neoplasms; Receptors, Estro | 2022 |
Modelling the procoagulatory effect of Anastrozole relative to ERα and ERβ expression in breast cancer cells.
Topics: Anastrozole; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Neoplasms; Receptors, Estro | 2022 |
Musculoskeletal manifestations in patients with malignant disease.
Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Comb | 2010 |
Musculoskeletal manifestations in patients with malignant disease.
Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Comb | 2010 |
Prevention strategies with aromatase inhibitors.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2004 |
Prevention strategies with aromatase inhibitors.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2004 |